(RTTNews) – AstraZeneca’s COVID-19 vaccine (AZN. L, AZN), Vaxzevria (ChAdOx1-S [recombinant], formerly AZD1222), received full marketing authorization in the European Union, the British primary said on Tuesday.
First, Vaxzevria was granted a conditional marketing authorisation due to the urgency of the COVID-19 pandemic.
The full marketing authorisation is based on the complete knowledge of efficacy and protection confirming the benefits of Vaxzevria.
The company noted that the full marketing authorization covers the use of Vaxzevria in either a number one vaccine series and as a heterologous booster third dose (with an approved mRNA vaccine against COVID-19) or homologous (all with the same vaccine).
For more information on fitness, rttnews. com